超低分割与常规放化疗治疗新诊断胶质母细胞瘤的随机试验
这项多中心III期随机试验因入组缓慢提前终止(n=135/474),比较超低分割(6x6Gy)与标准(30x2Gy)放化疗。超低分割组中位OS较短(13.0 vs 21.0个月),6个月后死亡率更高(HR 2.54),放射性坏死更常见(47.8% vs 16.2%),未能证明非劣效。
要点
- 超低分割组中位OS 13.0个月,标准组21.0个月。
- 6个月后超低分割组死亡风险更高(HR 2.54,p<0.001)。
- 超低分割组放射性坏死/假性进展更常见(47.8% vs 16.2%)。
核心结论
- 6x6Gy超低分割放化疗方案未能证明非劣效于标准30x2Gy放化疗。
- 超低分割方案与更差生存和更多放射性坏死相关,不应替代标准放化疗。
研究设计与样本
- 多中心III期随机对照试验,1:1随机分配至超低分割(6x6Gy/2周)或标准(30x2Gy/6周)放疗,均联合同步及6周期辅助替莫唑胺。
- 入组新诊断胶质母细胞瘤成人患者,Karnofsky功能状态评分≥70。
- 计划样本量474例,因入组缓慢提前终止,实际入组135例(试验组67例,标准组68例)。
- 主要终点为2年总生存(OS),非劣效界值为风险比(HR)1.2。
主要发现
- 超低分割组中位OS为13.0个月(95%CI 10.3-15.7),标准组为21.0个月(95%CI不可估计)。
- 时依分析显示前6个月两组生存相似(HR 0.99,95%CI 0.39-2.50),此后超低分割组死亡率更高(HR 2.54,95%CI 1.57-4.09,p<0.001)。
- 放射性坏死或假性进展在超低分割组更常见(47.8% vs 16.2%;HR 5.20,95%CI 2.56-10.58),6-12个月地塞米松使用增加。
- 未观察到4-5级毒性。
关键数值与推荐
- 非劣效界值为HR 1.2,主要终点2年OS。
- 超低分割方案为6x6Gy(2周),标准方案为30x2Gy(6周)。
- 超低分割组放射性坏死/假性进展发生率47.8%,标准组16.2%。
临床怎么用
- 标准30x2Gy同步及辅助替莫唑胺仍为新诊断胶质母细胞瘤的标准治疗。
- 6x6Gy超低分割方案不应替代标准放化疗。
- 超低分割治疗时需警惕放射性坏死和假性进展风险,以及地塞米松使用增加。
局限性
- 试验因入组缓慢提前终止,实际样本量135例远低于计划的474例。
- 标准组中位OS的95%CI不可估计。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In glioblastoma, standard first-line chemoradiation since the 2005 EORTC/NCIC trial is 30x2Gy with concurrent and adjuvant temozolomide. A phase II study suggested ultra-hypofractionation (6x6Gy) may offer comparable survival, with reduced treatment time and costs, potentially improving health-related quality of life (HRQoL). This phase III randomized trial (Netherlands Trial Registry, NL72953.041.20) evaluated non-inferiority of ultra-hypofractionated temozolomide chemoradiation in glioblastoma patients. PATIENTS AND METHODS: Adults with newly diagnosed glioblastoma and a Karnofsky performance status ≥70 were randomized (1:1) to ultra-hypofractionated (6x6Gy in 2 weeks) or standard (30x2Gy in 6 weeks) radiotherapy, both with concurrent and 6 cycles of adjuvant temozolomide. The primary endpoint was 2-year overall survival (OS); the non-inferiority margin was a hazard ratio of 1.2. Secondary outcomes included progression-free survival (PFS) and toxicity. RESULTS: Enrollment stopped early, due to slow accrual (n=135/474 planned, 67 experimental, 68 standard). Median OS was shorter in the experimental arm: 13.0 months (95% CI 10.3-15.7) versus 21.0 months (95% CI not estimable). In a time-dependent analysis, survival was similar in the first 6 months (HR 0.99, 95% CI 0.39-2.50), but mortality was higher thereafter (HR 2.54, 95% CI 1.57-4.09, p < 0.001). Radiation necrosis or pseudoprogression was more frequent after ultra-hypofractionation (47.8% vs 16.2%; HR 5.20, 95% CI 2.56-10.58), with increased dexamethasone use at 6-12 months. No grade 4-5 toxicities were observed. CONCLUSION: Non-inferiority of the 6x6 Gy chemoradiation regimen could not be demonstrated. This ultra-hypofractionated regimen was associated with inferior survival and increased radiation necrosis, and therefore should not replace standard chemoradiation.
引用
- de Jong AM, van der Boog ATJ, Wester G, et al. Ultra-hypofractionated versus conventional chemoradiation for newly diagnosed glioblastoma: Survival and toxicity results of a multicenter randomized trial. Radiother Oncol. 2026. PMID: 42570798. doi:10.1016/j.radonc.2026.111726
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。